Medication and Financial Rewards to Help People With HIV Quit Smoking
Tests quit-smoking medicines plus financial rewards in adults with HIV who smoke.
Plain-language title generated from the registry record
Registry title: Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial
Key facts
- Where
- Bridgeport, Brooklyn, Jersey City, New Haven, and Paterson, United StatesSee the 5 sites
- Phase
- Phase 4
Where in United States
- Bridgeport Hospital Primary Care Center Infectious Disease ClinicBridgeport, United StatesNo longer taking part
- Special Treatment And Research (STAR) at SUNY DownstateBrooklyn, United StatesNo longer taking part
- Center for Comprehensive Care at Jersey City Medical CenterJersey City, United StatesNo longer taking part
- Yale Center for Infectious DiseasesNew Haven, United StatesNo longer taking part
- Center for Comprehensive Care at St. Joseph's HealthPaterson, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT07835555
- Record updated
- 23 September 2026
- Original description
Cigarette smoking is an important cause of illness and death among persons with HIV (PWH). This project will study the impact of adding contingency management (use of financial rewards) to receiving medications and counseling on promoting smoking abstinence and other health outcomes among PWH. As treatments will be provided by clinical pharmacists and other team members in HIV clinics, factors relevant for implementing this model to inform real-world practice will also be evaluated.Read full original descriptionShow less
Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial
Cigarette smoking is an important cause of illness and death among persons with HIV (PWH). This project will study the impact of adding contingency management (use of financial rewards) to receiving medications and counseling on promoting smoking abstinence and other health outcomes among PWH. As treatments will be provided by clinical pharmacists and other team members in HIV clinics, factors relevant for implementing this model to inform real-world practice will also be evaluated.
Inclusion: Have been diagnosed with HIV; Receive care at one of the participating sites; Are >18 years old; Have smoked >100 cigarettes lifetime; Smoke everyday or some days; Smoke, on average, >5 cigarettes per day; and; Provide written informed consent.
Exclusion: Life-threatening or unstable medical, surgical, or psychiatric condition; Exclusive use of non-cigarette tobacco or nicotine products, including e-cigarettes; Self-report or urine testing confirming pregnancy, nursing, or trying to conceive; Anticipate being unable to return for follow-up for any reason, such as travel, planned procedure; Inability to provide >1 form of contact information; Inability to read or understand English or Spanish.